# Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

> **Newsylist Open Intelligence Dossier** · First detected: 2026-10-02 16:29 UTC · Category: Business · Sources: 2 · Current Velocity: 0.71

## Key People, Organizations & Locations
GLP-1s, Lilly, Why, Novo

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| sciencealert.com | Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial | 2026-10-02 15:13 | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxQbEtYS3k2bDJybHh0ZmxDVm9LOElUellCeGtNYjBSZW4yZGtueGJWb0Rrc2xodmswdkdnOFllWEVTNjhJRkpVRWx0RkdFcl96OG41R0FyenRMUnM0RW5DOXNSSk9rbzZwVGFhLVQ2TkIwamdsYmNjU0tiVDE3YV9RS29JMFA0WjdpTGhEWDJBNGU4VkhNZXlQeFM3cjZaMFRW?oc=5) |
| BioPharma Dive | 3 takeaways from a European obesity scientific meeting | 2026-10-02 15:13 | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxQSEFNVWZmUVBrMmhOMVV2Z1N4cjFSWmM2V0RZSy1MUDJONkFQejJ4RlJuWDVQblB0T25wVUdxZnBjYUUxWHNzdUZPUEN0cGdycGc0V2dRZEUyY0wxeXdkQXF5aUx1QnBFZzljbG5zTEtkVjRDNHhkX29IeGhTSE5GM0hSZmVyRUpKMUl4NjJ3ZFB2cUdiSzg5bGtmaw?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-10-02/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of-obesity-drugs*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*